- Voyageur Pharmaceuticals (VM) has completed the design of its carbon-neutral pharmaceutical plant in Alberta
- The $30M plant is designed to process approximately 5,000 tonnes per year of Frances Creek USP-grade barium sulphate (barite) concentrate
- Brent Willis, Voyageur CEO, sat down with Sabrina Cuthbert to discuss the news
- Voyageur is focused on the development of barium, iodine, and carbon APIs, as well as imaging contrast agents for the medical radiology marketplace
- Voyageur Pharmaceuticals (VM) opened trading at $0.09 per share
Voyageur Pharmaceuticals (VM) has completed the design of its carbon-neutral pharmaceutical plant in Alberta.
ACH Engineering Inc has estimated the total capital cost to be $30M (excluding land). The plant is designed to process approximately 5,000 tonnes per year of Frances Creek USP-grade barium sulphate (barite) concentrate.
The manufacturing facility is designed to produce revenue streams from pharmaceutical barium and iodine contrast media products for the radiology drug market.
Brent Willis, Voyageur CEO, sat down with Sabrina Cuthbert to discuss the news.
“North America is experiencing critical pharmaceutical supply chain challenges. It is becoming paramount for Canadian companies to focus on the domestic production of pharmaceuticals to fulfill the needs of our healthcare system in North America. Voyageur’s integrative approach to carbon-neutral contrast media manufacturing will become an important factor for healthcare security, with a strong focus on our environment. Building the first carbon-neutral pharmaceutical facility in Alberta, Canada, will be a major milestone for Voyageur. The added benefit of de-carbonizing our customer base by utilizing our carbon credits will make our product line unique and attractive to ensure potential high growth.”
Voyageur’s objective is to create a fully integrated, secure, environmentally responsible supply chain of barium, iodine, and fullerene contrast media for the North American and global markets.
Voyageur is focused on the development of barium, iodine, and carbon APIs, as well as imaging contrast agents for the medical radiology marketplace
Voyageur Pharmaceuticals (VM) opened trading at $0.09 per share.
